AC Immune (ACIU) Enterprise Value (2016 - 2025)
AC Immune (ACIU) has disclosed Enterprise Value for 9 consecutive years, with -$188.9 million as the latest value for Q4 2024.
- On a quarterly basis, Enterprise Value fell 62.64% to -$188.9 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$188.9 million, a 62.64% decrease, with the full-year FY2024 number at -$188.9 million, down 64.67% from a year prior.
- Enterprise Value was -$188.9 million for Q4 2024 at AC Immune, down from -$116.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$116.2 million in Q4 2023 to a low of -$249.9 million in Q4 2020.
- A 5-year average of -$179.4 million and a median of -$188.9 million in 2024 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: skyrocketed 40.81% in 2022, then crashed 62.64% in 2024.
- AC Immune's Enterprise Value stood at -$249.9 million in 2020, then grew by 13.97% to -$215.0 million in 2021, then surged by 40.81% to -$127.2 million in 2022, then rose by 8.7% to -$116.2 million in 2023, then plummeted by 62.64% to -$188.9 million in 2024.
- Per Business Quant, the three most recent readings for ACIU's Enterprise Value are -$188.9 million (Q4 2024), -$116.2 million (Q4 2023), and -$127.2 million (Q4 2022).